Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 105, Issue 50, Pages 20004-20008Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.0810899105
Keywords
galanin receptor 2; nerve injury; neuropeptide; pain treatment; sensory neuron
Categories
Funding
- Swedish Medical Research Council [04X-2887]
- Marianne and Marcus Wallenberg Foundation
- Knut and Alice Wallenberg Foundation
Ask authors/readers for more resources
Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase beta 3 (PLC beta 3) in mouse and human DRG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treatment of such animals with the unselective PLC inhibitor U73122 caused a rapid and long-lasting (48-h) increase in pain threshold. Thus, inhibition of PLC may provide a way to treat neuropathic pain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
